fakta.uk
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. Hospitals scored a win in Medicare’s final outpatient […]
After the largest ground water contamination in New Hampshire history, a state-commissioned study released this fall found significantly elevated rates of kidney cancer in the town of Merrimack. Residents fear that toxic “forever chemicals” are to blame. But to pin down a cause, the researchers need millions in funding. With federal dollars in flux, it’s […]
Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Sandy Tibke and Josh Gryniewicz. Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t […]
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got some spicy comments from Mark Cuban, and a pair of biotech Q&As. Let’s get to it. How Mark Cuban plans to ‘f— up’ health care This week, my colleagues and I scheduled […]
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can […]
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday. Do you wish your group chat could discuss both the latest Olivia Nuzzi revelations and STAT’s recent RFK Jr. profile … but they don’t all have […]
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. New warnings and restrictions placed […]
Johnson & Johnson said Monday it will purchase Halda Therapeutics and its experimental prostate cancer drugs for $3.05 billion, marking the first major buyout for a startup built around a field that has attracted significant investment but not yet secured any drug approvals. Over the last decade, the drug industry has been excited over so-called PROTACs: […]
A version of this essay first appeared on the website of the U.S. PIRG Education Fund. With the rise of ChatGPT and social media companies like Snapchat and Instagram integrating AI chatbots into their platforms, conversing with an AI companion has become a regular part of many people’s lives. One recent study found that nearly 75% of teens […]
